Small molecule · Antagonist of calcitonin gene-related peptide receptor (CALCRL) · developed by Pfizer
Rimegepant is a calcitonin gene-related peptide receptor antagonist that blocks CGRP signaling at its receptor. It is studied in acute treatment of migraine and in irritable bowel syndrome.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.
Acute Treatment of MigraineIrritable Bowel Syndrome
Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →